Literature DB >> 12637330

Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia.

M William Lensch1, Marc Tischkowitz, Tracy A Christianson, Carol A Reifsteck, S Ashley Speckhart, Petra M Jakobs, Michael E O'Dwyer, Susan B Olson, Michelle M Le Beau, Shirley V Hodgson, Christopher G Mathew, Richard A Larson, Grover C Bagby.   

Abstract

Myelodysplastic and leukemic stem cell clones that evolve in children and adults with Fanconi anemia universally bear complex cytogenetic abnormalities. The abnormalities are generally recurring deletions or chromosomal loss and involve precisely the same chromosomes with the same frequency as has been described in marrow cells from patients with secondary acute leukemia induced by alkylating agents. Reasoning that acquired Fanconi anemia protein dysfunction might contribute to cytogenetic instability in secondary acute myelogenous leukemia (AML) cells, we analyzed leukemic cells bearing characteristic complex cytogenetic defects obtained from a 68-year-old man whose lymphoblasts showed no evidence of Fanconi anemia. Unlike the lymphoblasts, this myeloid leukemia cell line (UoC-M1) was hypersensitive to mitomycin-C (MMC) and diepoxybutane (DEB) and exhibited a marked decrease in nuclear FANCA, FANCG, and FANCD2-L. Retroviral transduction of FANCA significantly reduced MMC sensitivity but FANCF, FANCG, and FANCC did not. Overexpression of FANCA restored levels of both FANCA and FANCG, whereas overexpression of FANCG or FANCC did not restore FANCA levels. The molecular mass of cytoplasmic FANCA, FANCG, FANCC, and nuclear FANCD2 were normal. All exons of FANCA and FANCG were sequenced, and no mutations were found. We conclude that perturbations of as yet unidentified factors that govern the binding activity or intracellular localization of FANCA may promote cytogenetic instability and clonal progression in patients with AML who do not have Fanconi anemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12637330     DOI: 10.1182/blood-2002-09-2781

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

Review 1.  Fanconi anaemia: from a monogenic disease to sporadic cancer.

Authors:  Antonio Valeri; Sandra Martínez; José A Casado; Juan A Bueren
Journal:  Clin Transl Oncol       Date:  2011-04       Impact factor: 3.405

2.  Natural gene therapy in monozygotic twins with Fanconi anemia.

Authors:  Anuj Mankad; Toshiyasu Taniguchi; Barbara Cox; Yassmine Akkari; R Keaney Rathbun; Lora Lucas; Grover Bagby; Susan Olson; Alan D'Andrea; Markus Grompe
Journal:  Blood       Date:  2006-01-05       Impact factor: 22.113

3.  Polymorphic variations in the FANCA gene in high-risk non-BRCA1/2 breast cancer individuals from the French Canadian population.

Authors:  Nadhir Litim; Yvan Labrie; Sylvie Desjardins; Geneviève Ouellette; Karine Plourde; Pascal Belleau; Francine Durocher
Journal:  Mol Oncol       Date:  2012-09-11       Impact factor: 6.603

Review 4.  Scientific and clinical opportunities for modeling blood disorders with embryonic stem cells.

Authors:  M William Lensch; George Q Daley
Journal:  Blood       Date:  2005-12-06       Impact factor: 22.113

Review 5.  Maintenance of genome stability by Fanconi anemia proteins.

Authors:  Anna Palovcak; Wenjun Liu; Fenghua Yuan; Yanbin Zhang
Journal:  Cell Biosci       Date:  2017-02-22       Impact factor: 7.133

6.  Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling.

Authors:  A H Beck; C-H Lee; D M Witten; B C Gleason; B Edris; I Espinosa; S Zhu; R Li; K D Montgomery; R J Marinelli; R Tibshirani; T Hastie; D M Jablons; B P Rubin; C D Fletcher; R B West; M van de Rijn
Journal:  Oncogene       Date:  2009-11-09       Impact factor: 9.867

Review 7.  The Fanconi anemia pathway and ubiquitin.

Authors:  Céline Jacquemont; Toshiyasu Taniguchi
Journal:  BMC Biochem       Date:  2007-11-22       Impact factor: 4.059

Review 8.  The ubiquitin system, disease, and drug discovery.

Authors:  Matthew D Petroski
Journal:  BMC Biochem       Date:  2008-10-21       Impact factor: 4.059

9.  Leukemic survival factor SALL4 contributes to defective DNA damage repair.

Authors:  F Wang; C Gao; J Lu; H Tatetsu; D A Williams; L U Müller; W Cui; L Chai
Journal:  Oncogene       Date:  2016-05-02       Impact factor: 9.867

Review 10.  Recent advances in understanding hematopoiesis in Fanconi Anemia.

Authors:  Grover Bagby
Journal:  F1000Res       Date:  2018-01-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.